Altaris Acquires Minaris Regenerative Medicine from Resonac

Altaris Acquires WuXi AppTec's Advanced Therapies U.S. and U.K. Operations (including OXGENE)

December 24, 2024

Biotechnology

Altaris, a New York-based healthcare-focused investment firm, acquired the U.S. and U.K. operations of WuXi AppTec's Advanced Therapies unit (including OXGENE). Advanced Therapies will be renamed and headquartered in the United States and Altaris intends to combine it with its recently acquired Minaris Regenerative Medicine to form Minaris Advanced Therapies, expanding cell-therapy CDMO capabilities and global footprint.

Altaris Capital Partners Majority Recapitalizes Minnetronix Medical

February 3, 2021

Medical Devices

Altaris Capital Partners has completed a majority recapitalization of Minnetronix Medical, expanding a relationship in place since 2015 when Altaris was a minority investor. The transaction provides Minnetronix — a Saint Paul, Minnesota-based medical device product development and contract manufacturing partner — with capital and partnership support to accelerate its growth and product strategy.

Altaris Combines Kindeva Drug Delivery and Meridian Medical Technologies

December 13, 2022

Medical Devices

Altaris has completed the combination of its portfolio companies Kindeva Drug Delivery and Meridian Medical Technologies into a single, global drug‑device CDMO that will operate under the Kindeva name. The combined company expands capabilities across parenteral, inhalation, transdermal and intradermal delivery formats; Milton Boyer (formerly Meridian CEO) will lead the combined business.

Altaris Capital Partners Acquires Meridian Medical Technologies from Pfizer

December 30, 2021

Medical Devices

Altaris Capital Partners has entered into an agreement to acquire Meridian Medical Technologies from Pfizer. Meridian, a pioneer in emergency response drug-device combination products and auto-injectors with facilities in St. Louis, Missouri and Columbia, Maryland and more than 750 employees, will become an Altaris portfolio company to expand the firm's capabilities in medical countermeasures and emergency response solutions.

Altaris Acquires 51% Stake in Solesis from Michelin

June 1, 2021

Medical Devices

Altaris Capital Partners has completed the acquisition of a 51% stake in Solesis from Michelin, with Michelin retaining a 49% ownership interest and partnering with Altaris to build Solesis as an independent company. Solesis, a U.S.-based biomaterials and medical-device components manufacturer operating through The Secant Group, Charter Medical and SanaVita Medical, employs approximately 360 people across production facilities in Pennsylvania and North Carolina.

Kindeva Drug Delivery (Altaris) Acquires Summit Biosciences

January 18, 2024

Medical Devices

Kindeva Drug Delivery, an operating company of healthcare investor Altaris, has acquired Summit Biosciences from its founding family shareholders. The acquisition adds Summit’s FDA- and EMA-approved 55,000 sq. ft. cGMP intranasal CDMO facility in Lexington, Kentucky, expanding Kindeva’s nasal drug‑delivery platform and global manufacturing footprint.